HomeCompareCTXRW vs O

CTXRW vs O: Dividend Comparison 2026

CTXRW yields 1387.93% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTXRW wins by $346908156.06M in total portfolio value
10 years
CTXRW
CTXRW
● Live price
1387.93%
Share price
$0.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$346908156.10M
Annual income
$303,843,436,712,884.44
Full CTXRW calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — CTXRW vs O

📍 CTXRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTXRWO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTXRW + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTXRW pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTXRW
Annual income on $10K today (after 15% tax)
$117,973.63/yr
After 10yr DRIP, annual income (after tax)
$258,266,921,205,951.75/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, CTXRW beats the other by $258,266,921,201,614.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTXRW + O for your $10,000?

CTXRW: 50%O: 50%
100% O50/50100% CTXRW
Portfolio after 10yr
$173454078.07M
Annual income
$151,921,718,358,993.60/yr
Blended yield
87.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

CTXRW
No analyst data
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTXRW buys
0
O buys
0
No recent congressional trades found for CTXRW or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTXRWO
Forward yield1387.93%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$346908156.10M$34.2K
Annual income after 10y$303,843,436,712,884.44$5,102.74
Total dividends collected$343747776.19M$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: CTXRW vs O ($10,000, DRIP)

YearCTXRW PortfolioCTXRW Income/yrO PortfolioO Income/yrGap
1← crossover$149,493$138,792.51$10,818$608.16+$138.7KCTXRW
2$2,099,063$1,939,106.48$11,787$741.68+$2.09MCTXRW
3$27,692,262$25,446,263.94$12,946$911.00+$27.68MCTXRW
4$343,373,046$313,742,325.46$14,345$1,127.94+$343.36MCTXRW
5$4,003,185,043$3,635,775,884.26$16,056$1,409.05+$4003.17MCTXRW
6$43,897,781,482$39,614,373,485.65$18,171$1,777.83+$43897.76MCTXRW
7$452,951,824,425$405,981,198,239.62$20,820$2,268.21+$452951.80MCTXRW
8$4,399,656,810,870$3,914,998,358,735.43$24,188$2,929.90+$4399656.79MCTXRW
9$40,247,401,294,059$35,539,768,506,427.31$28,533$3,837.11+$40247401.27MCTXRW
10$346,908,156,097,527$303,843,436,712,884.44$34,235$5,102.74+$346908156.06MCTXRW

CTXRW vs O: Complete Analysis 2026

CTXRWStock

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Full CTXRW Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this CTXRW vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTXRW vs SCHDCTXRW vs JEPICTXRW vs KOCTXRW vs MAINCTXRW vs STAGCTXRW vs ADCCTXRW vs NNNCTXRW vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.